‘Young blood’ company Ambrosia halts patient treatments after FDA warning

A company that charged patients thousands of dollars for infusions of blood plasma from younger donors said Tuesday that it had stopped treating patients after the Food and Drug Administration warned consumers against such treatments, purported to prevent aging and memory loss.

The company, Ambrosia, said on its website that it had “ceased patient treatments.” The announcement came hours after the FDA issued a statement saying there is no proof that plasma from young donors can be used as a treatment for dementia, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease or post-traumatic stress disorder, as some companies have claimed.

The plasma infusions can also be dangerous, the agency added, because they are associated with infectious, allergic, respiratory and cardiovascular risks.

Full story at NBC News